Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Immunopharma Plus D O O has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This portfolio is managed by a single distinct examiner and a sole distinct art unit. KIM, DANIELLE A is the busiest examiner, holding 1 pending office action.
The active matter represents the total current prosecution activity for this entity. Because there is only a single distinct examiner, KIM, DANIELLE A, the prosecution strategy is focused on a single individual's feedback. The use of a sole distinct art unit in the Biotechnology & Pharmaceuticals sector indicates that the pending application is being reviewed within a specific technical discipline without broader distribution. For practitioners, this means that the prosecution outcome is highly sensitive to the specific interpretations of KIM, DANIELLE A. The lack of multiple pending actions or examiners suggests a very targeted or early-stage patent strategy where every procedural step carries significant weight for the overall portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIM, DANIELLE A | 1 | 37.1% | +56.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17287852 | ORAL AMINODIHYDROPHTHALAZINEDIONE COMPOSITIONS AND THEIR USE IN THE TREATMENT OF NON-VIRAL HEPATITIS | KIM, DANIELLE A | 20d |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17287852 | ORAL AMINODIHYDROPHTHALAZINEDIONE COMPOSITIONS AND THEIR USE IN THE TREATMENT OF NON-VIRAL HEPATITIS | KIM, DANIELLE A | 1613 | §103 | Final Rejection | 20d | Pending | Apr 22, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial